Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 157

    1.

    Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario.

    Miniati I, Valentini G, Cerinic MM.

    Arthritis Res Ther. 2009;11(1):103. Epub 2009 Jan 23.

    PMID:
    19226435
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group.

    Arthritis Rheum. 2007 May;56(5):1676-84.

    PMID:
    17469162
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

    Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

    Ann N Y Acad Sci. 2007 Sep;1110:271-84.

    PMID:
    17911442
    [PubMed - indexed for MEDLINE]
    4.

    Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.

    Nannini C, West CP, Erwin PJ, Matteson EL.

    Arthritis Res Ther. 2008;10(5):R124. Epub 2008 Oct 20. Review. Erratum in: Arthritis Res Ther. 2009;11(2):408.

    PMID:
    18937831
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.

    Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH.

    Med Decis Making. 2008 Nov-Dec;28(6):926-37. Epub 2008 Apr 28.

    PMID:
    18443209
    [PubMed - indexed for MEDLINE]
    6.

    Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

    Fathi N, Furst DE, Clements PJ.

    Curr Rheumatol Rep. 2007 May;9(2):144-50.

    PMID:
    17502045
    [PubMed - indexed for MEDLINE]
    7.

    The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.

    Broad K, Pope JE.

    Med Sci Monit. 2010 Sep;16(9):RA187-90.

    PMID:
    20802426
    [PubMed - indexed for MEDLINE]
    8.

    Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.

    Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP; for Scleroderma Lung Study Investigators.

    Rheumatology (Oxford). 2009 Dec;48(12):1537-40. Epub 2009 Sep 23.

    PMID:
    19776222
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

    Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP.

    Curr Rheumatol Rep. 2009 Apr;11(2):111-9. Review.

    PMID:
    19296883
    [PubMed - indexed for MEDLINE]
    10.

    A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.

    Nadashkevich O, Davis P, Fritzler M, Kovalenko W.

    Clin Rheumatol. 2006 Mar;25(2):205-12. Epub 2005 Oct 14.

    PMID:
    16228107
    [PubMed - indexed for MEDLINE]
    11.

    Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

    Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

    Clin Rheumatol. 2007 Feb;26(2):168-72. Epub 2006 Apr 14.

    PMID:
    16614793
    [PubMed - indexed for MEDLINE]
    12.

    [Treatment of systemic sclerosis].

    van den Hoogen FH.

    Z Rheumatol. 2006 Jul;65(4):306, 308-10. Review. German.

    PMID:
    16819640
    [PubMed - indexed for MEDLINE]
    13.

    A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

    Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V.

    Rheumatology (Oxford). 2009 Jan;48(1):49-52. Epub 2008 Sep 24.

    PMID:
    18815156
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results.

    Airò P, Danieli E, Parrinello G, Antonioli CM, Cavazzana I, Toniati P, Franceschini F, Cattaneo R.

    Clin Exp Rheumatol. 2004 Sep-Oct;22(5):573-8.

    PMID:
    15485010
    [PubMed - indexed for MEDLINE]
    15.

    Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.

    Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A.

    Clin Exp Rheumatol. 2007 Mar-Apr;25(2):293-6.

    PMID:
    17543156
    [PubMed - indexed for MEDLINE]
    16.

    [Therapeutic management of systemic sclerosis].

    Mouthon L, Berezné A, Poiraudeau S, Guillevin L.

    Presse Med. 2006 Dec;35(12 Pt 2):1975-82. Review. French.

    PMID:
    17159724
    [PubMed - indexed for MEDLINE]
    17.

    Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

    Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group.

    Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. Epub 2007 Aug 23.

    PMID:
    17717203
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.

    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.

    Arthritis Rheum. 2007 Dec;56(12):4195-202.

    PMID:
    18050251
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.

    Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L.

    Scand J Rheumatol. 2006 Jan-Feb;35(1):35-8.

    PMID:
    16467039
    [PubMed - indexed for MEDLINE]
    20.

    Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.

    Vallance DK, Lynch JP 3rd, McCune WJ.

    Curr Opin Rheumatol. 1995 May;7(3):174-82. Review.

    PMID:
    7612408
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk